Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $19.00 Average Price Target from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $19.00.

ENTA has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, August 6th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. Finally, JPMorgan Chase & Co. cut their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $11.28 on Tuesday. The firm has a market capitalization of $238.90 million, a P/E ratio of -1.81 and a beta of 0.59. The company’s fifty day moving average is $13.19 and its two-hundred day moving average is $13.60. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.36. The company had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. Enanta Pharmaceuticals’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.27) EPS. On average, sell-side analysts forecast that Enanta Pharmaceuticals will post -5.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Scott T. Rottinghaus sold 4,299 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the transaction, the insider now owns 23,988 shares of the company’s stock, valued at $361,499.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $15.07, for a total value of $64,785.93. Following the completion of the transaction, the insider now owns 23,988 shares of the company’s stock, valued at $361,499.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the sale, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. The disclosure for this sale can be found here. Insiders own 13.64% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after purchasing an additional 18,003 shares during the last quarter. American Century Companies Inc. increased its stake in Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 7,287 shares during the period. Quest Partners LLC grew its stake in shares of Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the last quarter. Rhumbline Advisers raised its holdings in Enanta Pharmaceuticals by 4.7% in the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after purchasing an additional 1,548 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $35,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.